Country: Israel
Language: English
Source: Ministry of Health
CARBAMAZEPINE
MEGAPHARM LTD
N03AF
TABLETS PROLONGED RELEASE
CARBAMAZEPINE 600 MG
PER OS
Required
DESITIN ARZNEIMITTEL GMBH, GERMANY
CARBOXAMIDE DERIVATIVES
Treatment of epilepsy, trigeminal neuralgia, mania, prophylactic in manic depressive illness .
2020-09-30
Megapharm Ltd. Timonil SPC SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TIMONIL 300 RETARD, 300 mg/prolonged-release tablets TIMONIL 600 RETARD, 600 mg/prolonged-release tablets Active substance: Carbamazepine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 prolonged-release tablet conains: 300 or 600 mg carbamazepine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablets Timonil 300 retard Round, white, flat tablet cross-scored on both sides The tablet can be divided into equal doses. Timonil 600 retard White, oval, biconvex tablet scored on one side and engraved ‘T’ on the other side and with a protruding edge. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS For the treatment of: - Epilepsy - Trigeminal neuralgia - Mania - Prophylactic in manic depressive illness. Note: When switching from previous (non-prolonged release) pharmaceutical forms to Timonil retard, ensure a sufficiently high serum carbamazepine concentration. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Posology Treatment with Timonil retard should be started with a low, individualised, initial dose depending on the nature and severity of the disease. This is then gradually increased until the most effective maintenance dose is found. The daily dose is generally given in 1 – 2 single doses. The general daily dosage range lies between 400 -1200 mg carbamazepine. A total daily dose of 1600 mg should generally not be exceeded, since increased side effects occur at higher doses. Page 1 of 22 Megapharm Ltd. Timonil SPC The therapeutic dose should be established, especially in combination therapy, by measuring the plasma levels and depending on the efficacy. Experience has shown that the therapeutic carbamazepine concentration is between 4 and 12 µg/mL. In some instances the required dosage can vary considerably from the specified initial and maintenance doses (e.g. due to acceleration of metabolism by enzyme induction or due to drug in Read the complete document